Collaboration between UCB and Praxis for a KCNT1 Small Molecule

Written By Sarah Drislane

UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.

Sarah Drislane
Previous

Letter from our President
Next

ASO Therapies Show Promise for KCNT1